PFIZER's UNISOM ADVERTISING MOVING TO CLINE, DAVIS & MANN's
PFIZER's UNISOM ADVERTISING MOVING TO CLINE, DAVIS & MANN's new OTC unit effective Dec. 1. The ad agency's new OTC unit will begin official operations that day. In the meantime, the agency said it is hiring staff for the new division. The current ad agency handling the Unisom account is New York-based Avrett, Free & Ginsberg. Cline, Davis & Mann, New York, has appointed Senior VP and Management Supervisor Philip Roselin to manage the new OTC unit. Although staffers currently handling prescription product accounts at the medical specialty agency are expected to work with the new OTC unit, Cline, Davis said it plans to hire both account service personnel as well as creative staff to handle new OTC client accounts. The agency said it is currently in discussions with Pfizer about 1994 marketing plans for Unisom. The agency indicated that the ad campaign for the line, which includes a doxylamine-based sleep aid and a diphenhydramine/acetaminophen sleep aid for pain relief, will include television, radio and print ads. Unisom is currently the OTC division's only account although the agency said it is actively pursuing other OTC drug accounts. Cline, Davis & Mann already handles a number of prescription product accounts for Pfizer including Zithromax, Diflucan, Cardura and Unasyn. In addition, the agency handles professional advertising for Pfizer Consumer Healthcare's Plax mouth rinse. Cline, Davis & Mann also has a number of prescription product accounts with Rhone-Poulenc Rorer, Forest Labs and Parke-Davis.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.
The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.
There are now three draft versions of the legislative text that will overhaul the framework governing pharmaceuticals in the EU. Lawyers explain how the approaches proposed by the European Commission, European Parliament and Council of the EU differ and highlight implications for industry.